Scholar Rock Holding Corp

Scholar Rock Holding Corp

  • Price (USD)8.15
  • Today's Change0.16 / 2.00%
  • Shares traded21.65k
  • 1 Year change-66.28%
  • Beta--
Data delayed at least 15 minutes, as of Dec 06 2019 16:00 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is engaged in the development of monoclonal antibodies for treatment of diseases, such as neuromuscular disorders, cancer, fibrosis, and anemia. The Company's lead product candidate is SRK-015 that is in its pre-clinical stage of development. SRK-015 is a selective inhibitor of the activation of the growth factor myostatin in skeletal muscle. It is used to treat spinal muscular atrophy (SMA). The Company also develops other antibody programs that include TGFβ1 and BMP6. The TGFβ1 antibody program is focused on the development of antibodies that are specific inhibitors of TGFβ1 members.

  • Revenue in USD (TTM)12.92m
  • Net income in USD-54.39m
  • Incorporated2017
  • Employees69.00
  • Location
    Scholar Rock Holding Corp620 Memorial Dr Fl 2CAMBRIDGE 02139-4815United StatesUSA
  • Phone+1 (857) 259-3860
  • Fax+1 (302) 655-5049
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Chiasma Inc0.00-32.35m222.69m18.00--2.30-----1.14-,185.77----0.0137-------21.04---23.81--
Chromadex Corp42.27m-31.51m222.82m100.00--8.18--5.27-0.5641-0.56410.75570.45710.93762.289.40422,690.00-69.90-44.49-95.23-62.6954.4545.40-74.55-55.082.41-36.880.0128--48.8425.44-101.55--45.02--
Aeglea Bio Therapeutics Inc0.00-71.66m224.35m75.00--2.81-----2.42-2.420.002.760.00----0.00-83.63-55.82-96.53-61.49-------580.25----0.0008---25.30---62.83------
Eloxx Pharmaceuticals Inc0.00-53.27m229.22m29.00--5.06-----1.45-1.450.001.130.00----0.00-85.51---98.38-------------227.270.2451-------99.78------
Sutro Biopharma Inc50.52m-42.45m230.90m169.00--2.10--4.57-1.85-1.852.214.760.319--10.13343,653.10-26.81---34.80-------84.03------0.0936---25.75---79.38------
Inovio Pharmaceuticals Inc6.34m-114.66m233.02m281.00--6.85--36.78-1.18-1.180.06490.34020.0434--3.5122,544.70-78.96-39.71-95.28-49.23-----1,821.08-203.75---19.610.6599---27.8017.75-9.93--63.78--
Xeris Pharmaceuticals Inc1.69m-112.92m234.32m134.00--5.36--138.49-4.54-4.540.06881.620.0127--1.3018,800.00-85.00---94.22--98.05---6,673.58-----29.720.5711--58.42---126.26------
Scholar Rock Holding Corp12.92m-54.39m237.13m69.00--1.95--18.36-2.41-2.410.5364.100.0868----198,753.80-36.56---41.96-------421.03------0.00-------97.34------
Calithera Biosciences Inc0.00-87.63m237.69m79.00--1.97-----2.08-
RenovaCare Inc0.00-2.74m238.47m1.00--18.14-----0.0322-0.03220.000.15050.00----0.00-35.48-82.08-37.10-91.22------------0.00------42.51------
Syndax Pharmaceuticals Inc1.52m-60.88m239.11m38.00--5.43--157.72-2.11-2.110.05181.620.0175--6.4539,894.74-70.45-55.88-88.53-64.01-----4,016.10-4,078.62----0.00---28.04---21.64--37.53--
Minerva Neurosciences Inc0.00-55.47m239.62m13.00--4.32-----1.42-1.420.001.420.00----0.00-42.45-37.35-44.81-39.34------------0.00-------22.60------
Hookipa Pharma Inc-100.00bn-100.00bn241.38m60.00--1.92----------4.95----------------------------0.0404-------27.62------
ADMA Biologics Inc21.37m-55.76m244.98m318.00--6.78--11.46-1.12-1.120.41850.60890.17511.443.7467,196.38-45.68-67.44-50.90-79.07-82.30-35.08-260.93-257.953.76-7.140.7001---25.3740.82-50.24--60.52--
MannKind Corporation63.08m-47.39m245.63m225.00------3.89-0.2575-0.25750.3423-0.89490.89798.3518.43280,342.20-67.46-72.07-571.60--57.15---75.13-301.110.903-13.39----137.20--25.87---46.38--
Kalvista Pharmaceuticals Inc14.11m-25.72m251.82m45.00--2.58--17.85-1.48-1.480.80925.480.1153--1.50313,444.40-21.03---24.13-------182.37------0.00--92.13---31.71------
Data as of Dec 06 2019. Currency figures normalised to Scholar Rock Holding Corp's reporting currency: US Dollar USD

Institutional shareholders

53.35%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co.as of 30 Sep 20194.44m14.95%
Redmile Group LLCas of 30 Sep 20192.86m9.63%
Invus Public Equities Advisors LLCas of 30 Sep 20192.35m7.90%
Bellevue Asset Management AGas of 30 Sep 20192.20m7.40%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 20191.27m4.29%
The Vanguard Group, Inc.as of 30 Sep 2019908.17k3.06%
BlackRock Fund Advisorsas of 30 Sep 2019829.87k2.80%
Jefferies Investment Advisers LLCas of 30 Sep 2019408.93k1.38%
SSgA Funds Management, Inc.as of 30 Sep 2019322.53k1.09%
Norges Bank Investment Managementas of 31 Dec 2018255.00k0.86%
More ▼
Data from 31 Dec 2018 - 30 Sep 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.